Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 411 articles:
HTML format
Text format



Single Articles


    November 2018
  1. CUI SS, Du JJ, Liu SH, Meng J, et al
    Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27569.
    PubMed     Text format     Abstract available


  2. IRMEN F, Horn A, Meder D, Neumann WJ, et al
    Sensorimotor subthalamic stimulation restores risk-reward trade-off in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27576.
    PubMed     Text format     Abstract available


  3. JANKOVIC J
    Pathogenesis-targeted therapeutic strategies in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27534.
    PubMed     Text format    


  4. KRISTIANSEN M, Maple-Grodem J, Alves G, Arepalli S, et al
    A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27555.
    PubMed     Text format    


  5. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mov Disord. 2018 Nov 23. doi: 10.1002/mds.27492.
    PubMed     Text format     Abstract available


  6. SANJARI MOGHADDAM H, Aarabi MH
    Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27509.
    PubMed     Text format    


  7. DARVISH H, Bravo P, Tafakhori A, Azcona LJ, et al
    Identification of a large homozygous VPS13C deletion in a patient with early-onset Parkinsonism.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27516.
    PubMed     Text format    


  8. CORMIER-DEQUAIRE F, Bekadar S, Anheim M, Lebbah S, et al
    Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.
    Mov Disord. 2018 Nov 16. doi: 10.1002/mds.27519.
    PubMed     Text format     Abstract available


  9. LOFREDI R, Neumann WJ, Brucke C, Huebl J, et al
    Pallidal beta bursts in Parkinson's disease and dystonia.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27524.
    PubMed     Text format     Abstract available


  10. LYNCH WB, Tschumi CW, Sharpe AL, Branch SY, et al
    Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson's Model.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27541.
    PubMed     Text format     Abstract available


  11. MOHAMED IBRAHIM N, Ramli R, Koya Kutty S, Shah SA, et al
    Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus.
    Mov Disord. 2018 Nov 14. doi: 10.1002/mds.27526.
    PubMed     Text format    


  12. PICILLO M, Lizarraga KJ, Friesen EL, Chau H, et al
    Parkinsonism due to A53E alpha-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27506.
    PubMed     Text format     Abstract available


  13. FRIEDERICH A, Flinspach A, Suenkel U, Eschweiler GW, et al
    Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27539.
    PubMed     Text format    


  14. DELGADO-ALVARADO M, Dacosta-Aguayo R, Navalpotro-Gomez I, Gago B, et al
    Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27518.
    PubMed     Text format     Abstract available


  15. PUTZOLU M, Pelosin E, Ogliastro C, Lagravinese G, et al
    Anodal tDCS over prefrontal cortex improves dual-task walking in Parkinsonian patients with freezing.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27533.
    PubMed     Text format    


  16. KUIPERS DJS, Carr J, Bardien S, Thomas P, et al
    PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27501.
    PubMed     Text format     Abstract available


  17. POSTUMA RB
    Mediterranean diets and prodromal Parkinson's disease: A causal line, or a confound circle?
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27538.
    PubMed     Text format    


  18. ALBIN RL, Surmeier DJ, Tubert C, Sarter M, et al
    Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27540.
    PubMed     Text format    


  19. TANGNEY CC
    Diet to beat the odds of prodromal Parkinson's disease?
    Mov Disord. 2018 Nov 5. doi: 10.1002/mds.27520.
    PubMed     Text format    


  20. ESPAY AJ, Guskey MT, Norton JC, Coate B, et al
    Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
    Mov Disord. 2018 Nov 2. doi: 10.1002/mds.27488.
    PubMed     Text format     Abstract available


  21. OLANOW CW, Kenney C, Bandak S, Kieburtz KD, et al
    Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.
    Mov Disord. 2018 Nov 1. doi: 10.1002/mds.27497.
    PubMed     Text format    


  22. SAMOTUS O, Jog M
    Reply to: Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1829-1830.
    PubMed     Text format    


  23. MEADOWS SM, Conti MM, Gross L, Chambers NE, et al
    Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Mov Disord. 2018;33:1740-1749.
    PubMed     Text format     Abstract available


  24. DE SOUZA CP, Dos Santos MGG, Hamani C, Fonoff ET, et al
    Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1828-1829.
    PubMed     Text format    


    October 2018
  25. SACHELI MA, Murray DK, Vafai N, Cherkasova MV, et al
    Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study.
    Mov Disord. 2018 Oct 30. doi: 10.1002/mds.27498.
    PubMed     Text format     Abstract available


  26. TRINH J, Zeldenrust FMJ, Huang J, Kasten M, et al
    Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Mov Disord. 2018 Oct 24. doi: 10.1002/mds.27527.
    PubMed     Text format     Abstract available


  27. HABETS JGV, Heijmans M, Kuijf ML, Janssen MLF, et al
    An update on adaptive deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Oct 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  28. BETROUNI N, Delval A, Chaton L, Defebvre L, et al
    Electroencephalography-based machine learning for cognitive profiling in Parkinson's disease: Preliminary results.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27528.
    PubMed     Text format     Abstract available


  29. HUANG X, Ng SY, Chia NS, Acharyya S, et al
    Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27521.
    PubMed     Text format    


  30. WEERSINK JB, Eikelboom C, Dominguez Vega ZT, Maurits NM, et al
    Forward arm extension as a cue for gait initiation in Parkinson's patients.
    Mov Disord. 2018 Oct 17. doi: 10.1002/mds.27510.
    PubMed     Text format    


  31. TOSSERAMS A, Araujo R, Pringsheim T, Post B, et al
    Underrepresentation of women in Parkinson's disease trials.
    Mov Disord. 2018 Oct 11. doi: 10.1002/mds.27505.
    PubMed     Text format    


  32. MARAKI MI, Yannakoulia M, Stamelou M, Stefanis L, et al
    Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27489.
    PubMed     Text format     Abstract available


  33. VIRMANI T, Pillai L, Glover A, Doerhoff SM, et al
    Impaired step-length setting prior to turning in Parkinson's disease patients with freezing of gait.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27499.
    PubMed     Text format    


  34. FABER I, Martinez ARM, Martins CR Jr, Maia ML, et al
    SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa response.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27491.
    PubMed     Text format     Abstract available


  35. HOLDEN SK, Medina LD, Hoyt B, Sillau SH, et al
    Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27487.
    PubMed     Text format     Abstract available


  36. BLAUWENDRAAT C, Bras JM, Nalls MA, Lewis PA, et al
    Coding variation in GBA explains the majority of the SYT11-GBA Parkinson's disease GWAS locus.
    Mov Disord. 2018 Oct 9. doi: 10.1002.
    PubMed     Text format    


  37. WALDTHALER J, Tsitsi P, Seimyr GO, Benfatto MN, et al
    Eye movements during reading in parkinson's disease: A pilot study.
    Mov Disord. 2018 Oct 8. doi: 10.1002.
    PubMed     Text format    


  38. SMITH AM, Depp C, Ryan BJ, Johnston GI, et al
    Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells.
    Mov Disord. 2018 Oct 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  39. THALER A, Kozlovski T, Gurevich T, Bar-Shira A, et al
    Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27490.
    PubMed     Text format     Abstract available


  40. GREENAMYRE JT
    What's wrong with mitochondria in Parkinson's disease?
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed     Text format    


  41. VAN DER VELDEN RMJ, Mulders AEP, Drukker M, Kuijf ML, et al
    Network analysis of symptoms in a Parkinson patient using experience sampling data: An n = 1 study.
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  42. KOROS C, Simitsi A, Prentakis A, Beratis I, et al
    123I-FP-CIT SPECT [(123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T alpha-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27451.
    PubMed     Text format     Abstract available


  43. BEACH TG, Adler CH
    Importance of low diagnostic Accuracy for early Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27485.
    PubMed     Text format    


  44. BURCIU RG, Vaillancourt DE
    Imaging of Motor Cortex Physiology in Parkinson's Disease.
    Mov Disord. 2018 Oct 2. doi: 10.1002.
    PubMed     Text format     Abstract available



  45. Abstracts of the 2018 International Congress of Parkinson's Disease and Movement Disorders((R)).
    Mov Disord. 2018;33 Suppl 2:S1-S929.
    PubMed     Text format    


  46. DULOVIC M, Vos M
    Sleep dysfunction in Parkinson's disease: Novel molecular mechanism and implications for therapy.
    Mov Disord. 2018;33:1558-1559.
    PubMed     Text format    


  47. SCHRAG A
    Testing the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018;33:1518-1520.
    PubMed     Text format    


  48. WAGLE SHUKLA A, Fox SH
    Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
    Mov Disord. 2018;33:1560.
    PubMed     Text format    


    September 2018
  49. BARTHEL C, van Helvert M, Haan R, Janssen AM, et al
    Visual cueing using laser shoes reduces freezing of gait in parkinson's patients at home.
    Mov Disord. 2018 Sep 29. doi: 10.1002/mds.27455.
    PubMed     Text format    


  50. RAMIG L, Halpern A, Spielman J, Fox C, et al
    Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27460.
    PubMed     Text format     Abstract available


  51. SICILIANO M, Trojano L, Santangelo G, De Micco R, et al
    Fatigue in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27461.
    PubMed     Text format     Abstract available


  52. FABBRI M, Ferreira JJ, Lees A, Stocchi F, et al
    Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Mov Disord. 2018 Sep 27. doi: 10.1002/mds.27475.
    PubMed     Text format     Abstract available


  53. VAN DER VELDEN RMJ, Broen MPG, Kuijf ML, Leentjens AFG, et al
    Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review.
    Mov Disord. 2018 Sep 17. doi: 10.1002/mds.27465.
    PubMed     Text format     Abstract available


  54. LOHLE M, Mangone G, Wolz M, Beuthien-Baumann B, et al
    Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27466.
    PubMed     Text format     Abstract available


  55. LUBOMSKI M, Hayes M, Kennerson M, Ellis M, et al
    A novel Parkinson's disease risk variant, p. W378R, in the Gaucher's disease GBA gene.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format    


  56. HOOGLAND J, van Wanrooij LL, Boel JA, Goldman JG, et al
    Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  57. MESTRE TA
    Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format    


  58. CHARVIN D, Di Paolo T, Bezard E, Gregoire L, et al
    An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27462.
    PubMed     Text format     Abstract available


  59. PALACIOS N, Hughes KC, Cereda E, Schwarzschild MA, et al
    Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  60. YORITAKA A, Ohtsuka C, Maeda T, Hirayama M, et al
    Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27472.
    PubMed     Text format    


  61. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Risk of drowning in people with Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27473.
    PubMed     Text format    


  62. PCHELINA S, Baydakova G, Nikolaev M, Senkevich K, et al
    Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations.
    Mov Disord. 2018 Sep 7. doi: 10.1002/mds.27393.
    PubMed     Text format     Abstract available


  63. GAARE JJ, Nido GS, Sztromwasser P, Knappskog PM, et al
    Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease.
    Mov Disord. 2018 Sep 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  64. GUO L, Normando EM, Shah PA, De Groef L, et al
    Oculo-visual abnormalities in Parkinson's disease: Possible value as biomarkers.
    Mov Disord. 2018;33:1390-1406.
    PubMed     Text format     Abstract available


  65. VAILLANCOURT DE, Lehericy S
    Illuminating basal ganglia and beyond in Parkinson's disease.
    Mov Disord. 2018;33:1373-1375.
    PubMed     Text format    


  66. GRONICH N, Abernethy DR, Auriel E, Lavi I, et al
    beta2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Mov Disord. 2018;33:1465-1471.
    PubMed     Text format     Abstract available


    August 2018
  67. INOUE KI, Miyachi S, Nishi K, Okado H, et al
    Recruitment of calbindin into nigral dopamine neurons protects against MPTP-Induced parkinsonism.
    Mov Disord. 2018 Aug 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  68. BERG D, Adler CH, Bloem BR, Chan P, et al
    Movement disorder society criteria for clinically established early Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27431.
    PubMed     Text format     Abstract available


  69. ROZANI V, Gurevich T, Giladi N, El-Ad B, et al
    Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27413.
    PubMed     Text format     Abstract available


  70. MESTRE TA, Shamy M, Benedetti F, Lang AE, et al
    Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27409.
    PubMed     Text format     Abstract available


  71. SIEURIN J, Andel R, Tillander A, Valdes EG, et al
    Occupational stress and risk for Parkinson's disease: A nationwide cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27439.
    PubMed     Text format     Abstract available


  72. DEFFAINS M, Iskhakova L, Katabi S, Israel Z, et al
    Longer beta oscillatory episodes reliably identify pathological subthalamic activity in Parkinsonism.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27418.
    PubMed     Text format     Abstract available


  73. WANNEVEICH M, Moisan F, Jacqmin-Gadda H, Elbaz A, et al
    Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27447.
    PubMed     Text format     Abstract available


  74. POSTUMA RB, Poewe W, Litvan I, Lewis S, et al
    Validation of the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27362.
    PubMed     Text format     Abstract available


  75. LERCHE S, Liepelt-Scarfone I, Wurster I, Schulte C, et al
    Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease.
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27427.
    PubMed     Text format     Abstract available


  76. WITEK N, Stebbins GT, Goetz CG
    What influences placebo and nocebo responses in Parkinson's disease?
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27416.
    PubMed     Text format     Abstract available


  77. PHILLIPS MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, et al
    Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial.
    Mov Disord. 2018 Aug 11. doi: 10.1002/mds.27390.
    PubMed     Text format     Abstract available


  78. MESTRE TA, Ferreira JJ
    The placebo response in Parkinson's disease and other movement disorders.
    Mov Disord. 2018;33:1193-1194.
    PubMed     Text format    


  79. SKORVANEK M, Gelpi E, Mechirova E, Ladomirjakova Z, et al
    alpha-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa.
    Mov Disord. 2018;33:1366-1368.
    PubMed     Text format    


  80. FERREIRA JJ, Trenkwalder C, Mestre TA
    Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
    Mov Disord. 2018;33:1228-1235.
    PubMed     Text format     Abstract available


  81. QUATTRONE A, Barbagallo G, Cerasa A, Stoessl AJ, et al
    Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Mov Disord. 2018;33:1213-1227.
    PubMed     Text format     Abstract available


    July 2018
  82. PITCHER TL, Myall DJ, Pearson JF, Lacey CJ, et al
    Parkinson's disease across ethnicities: A nationwide study in New Zealand.
    Mov Disord. 2018 Jul 23. doi: 10.1002/mds.27389.
    PubMed     Text format     Abstract available


  83. GUPTA DK, Fahn S, Tatsuoka C, Kang UJ, et al
    Hoehn and Yahr stage 3 and postural stability item in the movement disorder society-unified Parkinson's disease rating scale.
    Mov Disord. 2018;33:1188-1189.
    PubMed     Text format    


  84. LOESCH DZ, Tassone F, Mellick GD, Horne M, et al
    Evidence for the role of FMR1 gray zone alleles as a risk factor for parkinsonism in females.
    Mov Disord. 2018;33:1178-1181.
    PubMed     Text format     Abstract available


  85. REYES CJ, Westenberger A
    An integrated OMICS approach unravels the elusive genetic cause of X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1095.
    PubMed     Text format    


  86. SANTENS P, De Letter M, Lees AJ, Krack P, et al
    Crime and Parkinson's: The jury is out.
    Mov Disord. 2018;33:1092-1094.
    PubMed     Text format    


  87. SKORVANEK M, Martinez-Martin P, Stebbins GT, Goetz CG, et al
    Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2018;33:1189-1190.
    PubMed     Text format    


  88. RAKOVIC A, Domingo A, Grutz K, Kulikovskaja L, et al
    Genome editing in induced pluripotent stem cells rescues TAF1 levels in X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1108-1118.
    PubMed     Text format     Abstract available


  89. EHGOETZ MARTENS KA, Shine JM, Walton CC, Georgiades MJ, et al
    Evidence for subtypes of freezing of gait in Parkinson's disease.
    Mov Disord. 2018;33:1174-1178.
    PubMed     Text format     Abstract available


    June 2018

  90. Abstracts of the 2nd Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2018;33.
    PubMed     Text format    


    May 2018
  91. SOMMERAUER M, Hansen AK, Parbo P, Fedorova TD, et al
    Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.
    Mov Disord. 2018 May 24. doi: 10.1002/mds.27411.
    PubMed     Text format     Abstract available


  92. CHARLES KA, Naudet F, Bouali-Benazzouz R, Landry M, et al
    Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease.
    Mov Disord. 2018 May 18. doi: 10.1002/mds.27377.
    PubMed     Text format     Abstract available


  93. LI J, Ruskey JA, Arnulf I, Dauvilliers Y, et al
    Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27385.
    PubMed     Text format     Abstract available


  94. DU G, Lewis MM, Sica C, He L, et al
    Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27318.
    PubMed     Text format     Abstract available


  95. TANIGUCHI D, Hatano T, Kamagata K, Okuzumi A, et al
    Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27365.
    PubMed     Text format     Abstract available


  96. HELDMANN M, Heeren J, Klein C, Rauch L, et al
    Neuroimaging abnormalities in individuals exhibiting Parkinson's disease risk markers.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27313.
    PubMed     Text format     Abstract available


  97. MEROLA A, Romagnolo A, Lopiano L, Espay AJ, et al
    Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer?"
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27421.
    PubMed     Text format    


  98. DE PABLO-FERNANDEZ E, Warner TT
    Autonomic dysfunction in Parkinson's disease: The hidden game changer?
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27422.
    PubMed     Text format    


  99. BAUFRETON J, Milekovic T, Li Q, McGuire S, et al
    Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27404.
    PubMed     Text format     Abstract available


  100. LEWIS MM, Du G, Baccon J, Snyder AM, et al
    Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27381.
    PubMed     Text format     Abstract available


  101. ORTUNO-LIZARAN I, Beach TG, Serrano GE, Walker DG, et al
    Phosphorylated alpha-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.
    Mov Disord. 2018 May 8. doi: 10.1002/mds.27392.
    PubMed     Text format     Abstract available


  102. LEWITT PA
    Comment on 'Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease' by Hiller et al.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27379.
    PubMed     Text format    


  103. CEDARBAUM JM
    Elephants, Parkinson's disease, and proof-of-concept clinical trials.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27398.
    PubMed     Text format    


    April 2018
  104. LIPSMEIER F, Taylor KI, Kilchenmann T, Wolf D, et al
    Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27376.
    PubMed     Text format     Abstract available


  105. SARDI SP, Cedarbaum JM, Brundin P
    Targeted therapies for Parkinson's disease: From genetics to the clinic.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27414.
    PubMed     Text format     Abstract available


  106. HANGANU A, Houde JC, Fonov VS, Degroot C, et al
    White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease.
    Mov Disord. 2018 Apr 23. doi: 10.1002/mds.27364.
    PubMed     Text format     Abstract available


  107. LEFAIVRE SC, Brown MJN, Almeida QJ
    Does cerebellar overactivity contribute to gait and balance deficits in Parkinson's disease?
    Mov Disord. 2018 Apr 20. doi: 10.1002/mds.27396.
    PubMed     Text format    


  108. MESTRE TA, Pont-Sunyer C, Kausar F, Visanji NP, et al
    Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mov Disord. 2018 Apr 17. doi: 10.1002/mds.27272.
    PubMed     Text format     Abstract available


  109. CONTARINO MF, Marinus J, van Hilten JJ
    Does deep brain stimulation of the subthalamic nucleus prolong survival in Parkinson's Disease?
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27384.
    PubMed     Text format    


  110. FRIEDMAN JH
    Quetiapine for Parkinson's Disease psychosis: Evidence-based medicine versus expert belief: A case study.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27378.
    PubMed     Text format    


  111. LANG AE, Espay AJ
    Disease modification in Parkinson's Disease: Current approaches, challenges, and future considerations.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27360.
    PubMed     Text format     Abstract available


  112. KASTEN M, Hartmann C, Hampf J, Schaake S, et al
    Genotype-phenotype relations for the Parkinson's Disease genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27352.
    PubMed     Text format     Abstract available


  113. AMANAT M, Salehi M
    Glitazone in Parkinson's Disease.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27397.
    PubMed     Text format    


  114. SCOTT KM, Williams-Gray CH
    Targeting aged astrocytes may be a new therapeutic strategy in Parkinson's disease.
    Mov Disord. 2018 Apr 6. doi: 10.1002/mds.27387.
    PubMed     Text format    


    March 2018
  115. MACEROLLO A, Brown MJN
    Beta oscillations and indirect pathway spiny projecting neurons: A selective neuronal mechanism linked to Parkinsonian pathophysiology?
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27388.
    PubMed     Text format    


  116. WEIR S, Samnaliev M, Kuo TC, Tierney TS, et al
    Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27302.
    PubMed     Text format     Abstract available


  117. KORDOWER JH, Burke RE
    Disease modification for Parkinson's disease: Axonal regeneration and trophic factors.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27383.
    PubMed     Text format     Abstract available


  118. COSSU G, Melis M, Sarchioto M, Melis M, et al
    6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27391.
    PubMed     Text format     Abstract available


  119. LITVAN I, Kieburtz K, Troster AI, Aarsland D, et al
    Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27345.
    PubMed     Text format     Abstract available


  120. KADHIM S, Pringsheim T, Le A, Fiest KM, et al
    Validating screening tools for depression in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27371.
    PubMed     Text format    


  121. MOGHADDAM HS, Arabi MH
    Synaptotagmin-11 Is a novel hotspot in the pathogenesis of parkin-linked Parkinson's disease: New implications for clinical targeting.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27369.
    PubMed     Text format    


  122. HOUSER MC, Chang J, Factor SA, Molho ES, et al
    Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27326.
    PubMed     Text format     Abstract available


  123. SIMUNI T, Siderowf A, Lasch S, Coffey CS, et al
    Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27361.
    PubMed     Text format     Abstract available


  124. FOX SH, Katzenschlager R, Lim SY, Barton B, et al
    International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27372.
    PubMed     Text format     Abstract available


  125. FASANO A, De Vloo P, Llinas M, Hlasny E, et al
    Magnetic resonance imaging-guided focused ultrasound thalamotomy in Parkinson tremor: Reoperation after benefit decay.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27348.
    PubMed     Text format    


  126. ANTONINI A, Moro E, Godeiro C, Reichmann H, et al
    Medical and surgical management of advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27340.
    PubMed     Text format     Abstract available


  127. FERNANDEZ HH, Boyd JT, Fung VSC, Lew MF, et al
    Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27338.
    PubMed     Text format     Abstract available


  128. HEINZEL S, Kasten M, Behnke S, Vollstedt EJ, et al
    Age- and sex-related heterogeneity in prodromal Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27349.
    PubMed     Text format    


  129. WEINTRAUB D, Troster AI, Marras C, Stebbins G, et al
    Initial cognitive changes in Parkinson's disease.
    Mov Disord. 2018 Mar 15. doi: 10.1002/mds.27330.
    PubMed     Text format     Abstract available


  130. CARDOSO F
    Vitamin B12 and Parkinson's disease: What is the relationship?
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27366.
    PubMed     Text format    


  131. BECK G, Maehara S, Chang PL, Papa SM, et al
    A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27341.
    PubMed     Text format     Abstract available


  132. CHRISTINE CW, Auinger P, Joslin A, Yelpaala Y, et al
    Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27301.
    PubMed     Text format     Abstract available


  133. PALMA JA, Kaufmann H
    Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.
    Mov Disord. 2018;33:372-390.
    PubMed     Text format     Abstract available


    February 2018
  134. SONG W, Kothari V, Velly AM, Cressatti M, et al
    Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27328.
    PubMed     Text format     Abstract available


  135. GOLDMAN JG, Holden SK, Litvan I, McKeith I, et al
    Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27323.
    PubMed     Text format     Abstract available


  136. MORALES-BRICENO H, Sanchez-Hernandez BE, Meyer E, Kurian MA, et al
    Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27294.
    PubMed     Text format    


  137. CENCI MA, Crossman AR
    Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27337.
    PubMed     Text format     Abstract available


  138. MENG Y, Voisin MR, Suppiah S, Kalia SK, et al
    Is there a role for MR-guided focused ultrasound in Parkinson's disease?
    Mov Disord. 2018 Feb 24. doi: 10.1002/mds.27308.
    PubMed     Text format    


  139. WEIL RS, Schwarzkopf DS, Bahrami B, Fleming SM, et al
    Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27311.
    PubMed     Text format     Abstract available


  140. PERAN P, Barbagallo G, Nemmi F, Sierra M, et al
    MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27307.
    PubMed     Text format     Abstract available


  141. ARGAUD S, Verin M, Sauleau P, Grandjean D, et al
    Facial emotion recognition in Parkinson's disease: A review and new hypotheses.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27305.
    PubMed     Text format     Abstract available


  142. FERNANDEZ-SANTIAGO R, Garrido A, Infante J, Gonzalez-Aramburu I, et al
    alpha-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27295.
    PubMed     Text format     Abstract available


  143. DAFSARI HS, Silverdale M, Strack M, Rizos A, et al
    Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2018 Feb 21. doi: 10.1002/mds.27283.
    PubMed     Text format     Abstract available


  144. FEDERICO A, Tinazzi M, Tamburin S
    MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27329.
    PubMed     Text format    


  145. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27339.
    PubMed     Text format    


  146. WYMAN-CHICK KA, Martin PK, Weintraub D, Sperling SA, et al
    Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27335.
    PubMed     Text format     Abstract available


  147. PARK JS, Koentjoro B, Klein C, Sue CM, et al
    Single heterozygous ATP13A2 mutations cause cellular dysfunction associated with Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27327.
    PubMed     Text format    


  148. SAMOTUS O, Parrent A, Jog M
    Spinal cord stimulation therapy for gait dysfunction in advanced Parkinson's disease patients.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.
    PubMed     Text format     Abstract available


  149. FAZIO P, Svenningsson P, Cselenyi Z, Halldin C, et al
    Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27316.
    PubMed     Text format     Abstract available


  150. BOUCA-MACHADO R, Lennaerts-Kats H, Bloem B, Ferreira JJ, et al
    Why palliative care applies to Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27309.
    PubMed     Text format    


  151. DAGAN M, Herman T, Harrison R, Zhou J, et al
    Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300.
    PubMed     Text format     Abstract available


  152. PALMA JA
    Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27347.
    PubMed     Text format    


  153. ABBASI N, Mohajer B, Abbasi S, Hasanabadi P, et al
    Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27284.
    PubMed     Text format     Abstract available


  154. MULAK A
    A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27304.
    PubMed     Text format    


  155. MAHLKNECHT P, Gasperi A, Djamshidian A, Kiechl S, et al
    Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27281.
    PubMed     Text format     Abstract available


  156. BAHIRAEE A, Ebrahimi R
    A noble pathological role for alpha-synuclein in triggering neurodegeneration of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27306.
    PubMed     Text format    


  157. CREED RB, Goldberg MS
    New developments in genetic rat models of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27296.
    PubMed     Text format     Abstract available


  158. WEINTRAUB D, Hamilton JL, Eberling J, Litvan I, et al
    At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27310.
    PubMed     Text format    


  159. LAGRAVINESE G, Pelosin E, Bonassi G, Carbone F, et al
    Gait initiation is influenced by emotion processing in Parkinson's disease patients with freezing.
    Mov Disord. 2018 Feb 2. doi: 10.1002/mds.27312.
    PubMed     Text format     Abstract available


  160. NAROS G, Grimm F, Weiss D, Gharabaghi A, et al
    Directional communication during movement execution interferes with tremor in Parkinson's disease.
    Mov Disord. 2018;33:251-261.
    PubMed     Text format     Abstract available


    January 2018
  161. NOYCE AJ, Dickson J, Rees RN, Bestwick JP, et al
    Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27282.
    PubMed     Text format     Abstract available


  162. MOREAU C, Duce JA, Rascol O, Devedjian JC, et al
    Iron as a therapeutic target for Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27275.
    PubMed     Text format    


  163. PAL G, Ouyang B, Verhagen L, Serrano G, et al
    Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27280.
    PubMed     Text format    


  164. CHEN V, Saez-Atienzar S
    A tango for two: Dopamine and alpha-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27248.
    PubMed     Text format    


  165. SAVICA R, Grossardt BR, Rocca WA, Bower JH, et al
    Parkinson disease with and without Dementia: A prevalence study and future projections.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27277.
    PubMed     Text format     Abstract available


  166. HIMMELBERG MM, West RJH, Wade AR, Elliott CJH, et al
    A perceptive plus in Parkinson's disease.
    Mov Disord. 2018 Jan 14. doi: 10.1002/mds.27240.
    PubMed     Text format    


  167. KIM IY, O'Reilly EJ, Hughes KC, Gao X, et al
    Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.
    Mov Disord. 2018 Jan 10. doi: 10.1002/mds.27279.
    PubMed     Text format     Abstract available


  168. GARCIA-SANZ P, Moratalla R
    The importance of cholesterol in Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27251.
    PubMed     Text format    


  169. GAO Y, Wilson GR, Stephenson SEM, Bozaoglu K, et al
    The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27270.
    PubMed     Text format     Abstract available


  170. AHMADI NS
    Mutant parkin-induced parkinsonism from an electrical point of view: Abnormal excitatory response to dopamine resolved after substitution.
    Mov Disord. 2018;33:71.
    PubMed     Text format    


    December 2017
  171. MEROLA A, Romagnolo A, Rosso M, Suri R, et al
    Autonomic dysfunction in Parkinson's disease: A prospective cohort study.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27268.
    PubMed     Text format     Abstract available


  172. MARRINAN SL, Otiker T, Vasist LS, Gibson RA, et al
    A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27259.
    PubMed     Text format     Abstract available


  173. BOWER JH, Grossardt BR, Rocca WA, Savica R, et al
    Prevalence of and indications for antipsychotic use in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27256.
    PubMed     Text format     Abstract available


  174. LIU Z, Tang B
    Novel Parkinson's disease risk loci identified through a meta-analysis of genome-wide association studies.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27276.
    PubMed     Text format    


  175. BOUTHOUR W, Wegrzyk J, Momjian S, Peron J, et al
    Short pulse width in subthalamic stimulation in Parkinson's disease: a randomized, double-blind study.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27265.
    PubMed     Text format     Abstract available


  176. ROOSEN DA, Singleton AB
    Leucine rich repeat kinase knockout (LRRK KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease.
    Mov Disord. 2017 Dec 19. doi: 10.1002/mds.27267.
    PubMed     Text format    


  177. PICCONI B, Hernandez LF, Obeso JA, Calabresi P, et al
    Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Mov Disord. 2017 Dec 8. doi: 10.1002/mds.27261.
    PubMed     Text format     Abstract available


  178. GOLDMAN JG, Andrews H, Amara A, Naito A, et al
    Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27232.
    PubMed     Text format     Abstract available


  179. KIEBURTZ K, Katz R, Olanow CW
    New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27220.
    PubMed     Text format    


  180. FERNANDES HJR
    Beyond the lysosome: Cholesterol role on endoplasmic reticulum and lipid droplets in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27249.
    PubMed     Text format    


  181. PADMANABHAN S, Burke RE
    Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27209.
    PubMed     Text format    


    November 2017
  182. LOZANO CS, Tam J, Lozano AM
    The changing landscape of surgery for Parkinson's Disease.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27228.
    PubMed     Text format     Abstract available


  183. BHATIA KP, Bain P, Bajaj N, Elble RJ, et al
    Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27121.
    PubMed     Text format     Abstract available


  184. SVENSSON E, Henderson VW, Szepligeti S, Stokholm MG, et al
    Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study.
    Mov Disord. 2017 Nov 29. doi: 10.1002/mds.27253.
    PubMed     Text format     Abstract available


  185. BUARD I, Sciacca DM, Martin CS, Rogers S, et al
    Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Nov 27. doi: 10.1002/mds.27246.
    PubMed     Text format    


  186. TROPEA TF, Xie SX, Rick J, Chahine LM, et al
    APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27204.
    PubMed     Text format     Abstract available


  187. KOHSAKA M, Oeda T, Umemura A, Tomita S, et al
    Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27243.
    PubMed     Text format    


  188. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27233.
    PubMed     Text format     Abstract available


  189. KULIKOVSKAJA L, Seibler P
    Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27262.
    PubMed     Text format    


  190. STEIGERWALD F, Timmermann L, Kuhn A, Schnitzler A, et al
    Pulse duration settings in subthalamic stimulation for Parkinson's disease.
    Mov Disord. 2017 Nov 22. doi: 10.1002/mds.27238.
    PubMed     Text format     Abstract available


  191. POCHARD C, Leclair-Visonneau L, Coron E, Neunlist M, et al
    Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27237.
    PubMed     Text format    


  192. WEAVER FM, Stroupe KT, Smith B, Gonzalez B, et al
    Survival in patients with Parkinson's disease after deep brain stimulation or medical management.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27235.
    PubMed     Text format     Abstract available


  193. DAFSARI HS, Reker P, Stalinski L, Silverdale M, et al
    Quality of life outcomes after subthalamic stimulation in Parkinson's disease depends on age.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27222.
    PubMed     Text format     Abstract available


  194. SYRKIN-NIKOLAU J, Neuville R, O'Day J, Anidi C, et al
    Coordinated reset vibrotactile stimulation shows prolonged improvement in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27223.
    PubMed     Text format    


  195. ELAHI E
    PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability.
    Mov Disord. 2017 Nov 16. doi: 10.1002/mds.27126.
    PubMed     Text format    


  196. HELMICH RC
    The cerebral basis of Parkinsonian tremor: A network perspective.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27224.
    PubMed     Text format     Abstract available


  197. GOETZ CG
    Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years?
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27214.
    PubMed     Text format    


  198. ARNALDI D, De Carli F, Fama F, Brugnolo A, et al
    Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27190.
    PubMed     Text format     Abstract available


  199. SCHNEIDER SA, Alcalay RN
    Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
    Mov Disord. 2017;32:1504-1523.
    PubMed     Text format     Abstract available


  200. SCHAPIRA AH
    What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease.
    Mov Disord. 2017;32:1499-1500.
    PubMed     Text format    


    October 2017
  201. SOHAIL S, Yu L, Schneider JA, Bennett DA, et al
    Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27200.
    PubMed     Text format     Abstract available


  202. LI W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, et al
    11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27183.
    PubMed     Text format     Abstract available


  203. METEREAU E, Beaudoin-Gobert M, Duperrier S, Thobois S, et al
    Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Mov Disord. 2017 Oct 27. doi: 10.1002/mds.27201.
    PubMed     Text format     Abstract available


  204. FASANO A, Canning CG, Hausdorff JM, Lord S, et al
    Falls in Parkinson's disease: A complex and evolving picture.
    Mov Disord. 2017 Oct 25. doi: 10.1002/mds.27195.
    PubMed     Text format     Abstract available


  205. WEINTRAUB D, Chahine LM, Hawkins KA, Siderowf A, et al
    Cognition and the course of prodromal Parkinson's disease.
    Mov Disord. 2017 Oct 24. doi: 10.1002/mds.27189.
    PubMed     Text format     Abstract available


  206. FENGLER S, Liepelt-Scarfone I, Brockmann K, Schaffer E, et al
    Cognitive changes in prodromal Parkinson's disease: A review.
    Mov Disord. 2017 Oct 5. doi: 10.1002/mds.27135.
    PubMed     Text format     Abstract available


  207. ASCHERIO A, Schwarzschild MA
    Dietary antioxidants and Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27194.
    PubMed     Text format    


  208. SAEED U, Masellis M
    Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27171.
    PubMed     Text format    


  209. MACLEOD AD, Dalen I, Tysnes OB, Larsen JP, et al
    Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27177.
    PubMed     Text format     Abstract available


  210. WEIL RS, Pappa K, Schade RN, Schrag AE, et al
    The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27176.
    PubMed     Text format    


  211. FORD KJ, Joop A, Memon RA, Wood KH, et al
    Pedestrian safety in patients with Parkinson's disease: A case-control study.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27124.
    PubMed     Text format     Abstract available


  212. STANDAERT DG
    What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.
    Mov Disord. 2017;32:1341-1342.
    PubMed     Text format    


    September 2017
  213. THEVATHASAN W, Debu B, Aziz T, Bloem BR, et al
    Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review.
    Mov Disord. 2017 Sep 28. doi: 10.1002/mds.27098.
    PubMed     Text format     Abstract available


  214. BIUNDO R, Weis L, Abbruzzese G, Calandra-Buonaura G, et al
    Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Mov Disord. 2017 Sep 27. doi: 10.1002/mds.27181.
    PubMed     Text format     Abstract available


  215. TESSITORE A, De Micco R, Giordano A, di Nardo F, et al
    Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27139.
    PubMed     Text format     Abstract available


  216. ROSE SJ, Harrast P, Donsante C, Fan X, et al
    Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27169.
    PubMed     Text format     Abstract available


  217. FULLARD ME, Xie SX, Marek K, Stern M, et al
    Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.
    Mov Disord. 2017 Sep 14. doi: 10.1002/mds.27127.
    PubMed     Text format     Abstract available


  218. SAME K, Ghazi Sherbaf F, Aarabi MH
    New link between Parkinson's and Alzheimer's: Research uncovers the role of mutant leucine rich repeat kinase 2 and amyloid precursor protein.
    Mov Disord. 2017 Sep 13. doi: 10.1002/mds.27170.
    PubMed     Text format    


  219. FRISALDI E, Carlino E, Zibetti M, Barbiani D, et al
    The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
    Mov Disord. 2017 Sep 12. doi: 10.1002/mds.27142.
    PubMed     Text format     Abstract available


  220. YANG F, Wolk A, Hakansson N, Pedersen NL, et al
    Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27120.
    PubMed     Text format     Abstract available


  221. HAN W, Sapkota S, Camicioli R, Dixon RA, et al
    Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27173.
    PubMed     Text format     Abstract available


  222. GHAHREMANI A, Chen R
    Deep brain stimulation modulates the shape of cortical beta oscillations in Parkinson's disease.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27144.
    PubMed     Text format    


  223. EUSEBI P, Giannandrea D, Biscetti L, Abraha I, et al
    Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27110.
    PubMed     Text format     Abstract available


  224. BRAKEDAL B, Flones I, Reiter SF, Torkildsen O, et al
    Glitazone use associated with reduced risk of Parkinson's disease.
    Mov Disord. 2017 Sep 1. doi: 10.1002/mds.27128.
    PubMed     Text format     Abstract available


  225. OBESO JA, Stamelou M, Goetz CG, Poewe W, et al
    Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
    Mov Disord. 2017;32:1264-1310.
    PubMed     Text format     Abstract available



  226. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative
    Mov Disord. 2017;32:e1-e19.
    PubMed     Text format    


    August 2017
  227. TREZZI JP, Galozzi S, Jaeger C, Barkovits K, et al
    Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27132.
    PubMed     Text format     Abstract available


  228. HEINTZ-BUSCHART A, Pandey U, Wicke T, Sixel-Doring F, et al
    The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27105.
    PubMed     Text format     Abstract available


  229. TURCANO P, Mielke MM, Josephs KA, Bower JH, et al
    Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27125.
    PubMed     Text format     Abstract available


  230. PARNETTI L, Paciotti S, Eusebi P, Dardis A, et al
    Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27136.
    PubMed     Text format     Abstract available


  231. BORGHAMMER P
    How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27138.
    PubMed     Text format     Abstract available


  232. OERTEL W, Eggert K, Pahwa R, Tanner CM, et al
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Mov Disord. 2017 Aug 21. doi: 10.1002/mds.27131.
    PubMed     Text format     Abstract available


  233. CHAUDHURI KR, Jenner P
    Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27104.
    PubMed     Text format    


  234. POLLARD EE
    Where we've gone "right" in the Parkinson's community.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27076.
    PubMed     Text format    


  235. ROCCA WA
    The future burden of Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27114.
    PubMed     Text format    


  236. MIYAUE N, Tada S, Ando R, Yabe H, et al
    cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27109.
    PubMed     Text format    


  237. BANDRES-CIGA S, Cookson MR
    Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder?
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27116.
    PubMed     Text format    


  238. GARCIA-SANZ P, Orgaz L, Bueno-Gil G, Espadas I, et al
    N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
    Mov Disord. 2017 Aug 5. doi: 10.1002/mds.27119.
    PubMed     Text format     Abstract available


  239. LILL CM, Klein C
    What would Dr. James Parkinson think today? The role of genetics in Parkinson's disease.
    Mov Disord. 2017;32:1115-1116.
    PubMed     Text format    


    July 2017
  240. CHUNG SJ, Shin JH, Cho KH, Lee Y, et al
    Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27106.
    PubMed     Text format     Abstract available


  241. DELPONT B, Lhommee E, Klinger H, Schmitt E, et al
    Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27101.
    PubMed     Text format     Abstract available


  242. OFORI E, Krismer F, Burciu RG, Pasternak O, et al
    Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Mov Disord. 2017 Jul 17. doi: 10.1002/mds.27100.
    PubMed     Text format     Abstract available


  243. THIBAULT L, Rascol O, Corvol JC, Ferreira J, et al
    New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
    Mov Disord. 2017 Jul 13. doi: 10.1002/mds.27055.
    PubMed     Text format    


  244. PAYAMI H
    The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27099.
    PubMed     Text format     Abstract available


  245. KOJOVIC M, Kassavetis P, Parees I, Georgiev D, et al
    Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27091.
    PubMed     Text format    


  246. CORREIA GUEDES L, Reimao S, Paulino P, Nunes RG, et al
    Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27083.
    PubMed     Text format    


  247. HEINZEL S, Bernhard FP, Roeben B, Nussbaum S, et al
    Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27062.
    PubMed     Text format    


  248. SAEZ-ATIENZAR S, Singleton AB
    Parkinson Disease and Clathrin Coat Dynamics at Synapses, Why Not?
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27097.
    PubMed     Text format    


  249. SONG N, Wang W, Jia F, Du X, et al
    Assessments of plasma ghrelin levels in the early stages of parkinson's disease.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27095.
    PubMed     Text format     Abstract available


  250. HUANG P, Tan YY, Liu DQ, Herzallah MM, et al
    Motor-symptom laterality affects acquisition in Parkinson's disease: A cognitive and functional magnetic resonance imaging study.
    Mov Disord. 2017;32:1047-1055.
    PubMed     Text format     Abstract available


  251. OBESO JA, Trenkwalder C
    What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society.
    Mov Disord. 2017;32:951-954.
    PubMed     Text format    


    June 2017
  252. ZABETIAN CP, Mata IF
    LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Mov Disord. 2017 Jun 28. doi: 10.1002/mds.27081.
    PubMed     Text format    


  253. GOETZ CG, Stebbins GT, Chung KA, Nicholas AP, et al
    Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
    Mov Disord. 2017 Jun 24. doi: 10.1002/mds.27092.
    PubMed     Text format    


  254. LHOMMEE E, Boyer F, Wack M, Pelissier P, et al
    Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
    Mov Disord. 2017 Jun 23. doi: 10.1002/mds.27065.
    PubMed     Text format     Abstract available


  255. STEINER LA, Neumann WJ, Staub-Bartelt F, Herz DM, et al
    Subthalamic beta dynamics mirror Parkinsonian bradykinesia months after neurostimulator implantation.
    Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27068.
    PubMed     Text format     Abstract available


  256. CHOTIBUT T, Meadows S, Kasanga EA, McInnis T, et al
    Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27077.
    PubMed     Text format     Abstract available


  257. BONET-PONCE L, Singleton AB
    Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27078.
    PubMed     Text format    


  258. CLAASSEN DO, Stark AJ, Spears CA, Petersen KJ, et al
    Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.
    Mov Disord. 2017 Jun 19. doi: 10.1002/mds.27047.
    PubMed     Text format     Abstract available


  259. PELOSI A
    Cell-specific alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
    Mov Disord. 2017 Jun 16. doi: 10.1002/mds.27071.
    PubMed     Text format    


  260. FRIEDMAN JH
    Drug-induced parkinsonism.
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27050.
    PubMed     Text format    


  261. ROCCA WA, Savica R, Grossardt BR
    Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27051.
    PubMed     Text format    


  262. HOOGLAND J, Boel JA, de Bie RMA, Geskus RB, et al
    Mild cognitive impairment as a risk factor for Parkinson's disease dementia.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27002.
    PubMed     Text format     Abstract available


  263. TITOVA N, Chaudhuri KR
    Personalized medicine in Parkinson's disease: Time to be precise.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27027.
    PubMed     Text format    


  264. LARSSON SC, Singleton AB, Nalls MA, Richards JB, et al
    No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study.
    Mov Disord. 2017 Jun 8. doi: 10.1002/mds.27069.
    PubMed     Text format     Abstract available


  265. ROSSI A, Berger K, Chen H, Leslie D, et al
    Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27063.
    PubMed     Text format     Abstract available


  266. KASSUBEK J, Huppertz HJ, Hoglinger GU
    Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27057.
    PubMed     Text format    


  267. KUMAR A
    Reprogramming the striatal stars: A new treatment option for Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27067.
    PubMed     Text format    


  268. QUATTRONE A, Nigro S
    MRI measures of brainstem in Parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27056.
    PubMed     Text format    


  269. MAHLKNECHT P, Akram H, Georgiev D, Tripoliti E, et al
    Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27042.
    PubMed     Text format     Abstract available


  270. PINA-FUENTES D, Little S, Oterdoom M, Neal S, et al
    Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.26959.
    PubMed     Text format    



  271. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2017;32 Suppl 2:S1-S1079.
    PubMed     Text format    


  272. MANDEMAKERS W, Quadri M, Stamelou M, Bonifati V, et al
    TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27061.
    PubMed     Text format     Abstract available


  273. PEREZ-SORIANO A, Arena JE, Dinelle K, Miao Q, et al
    PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27029.
    PubMed     Text format     Abstract available


  274. AKRAM H, Wu C, Hyam J, Foltynie T, et al
    l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.
    Mov Disord. 2017;32:874-883.
    PubMed     Text format     Abstract available


  275. VAILLANCOURT DE
    What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease.
    Mov Disord. 2017;32:805-806.
    PubMed     Text format    


  276. LENKA A, Pal PK
    "Miro" in Parkinson's disease: Here, there, everywhere!
    Mov Disord. 2017;32:839.
    PubMed     Text format    


    May 2017
  277. NG ASL, Tan EK
    Linking statins and lipids in Parkinson's disease.
    Mov Disord. 2017 May 27. doi: 10.1002/mds.27053.
    PubMed     Text format    


  278. DELGADO-ALVARADO M, Gago B, Gorostidi A, Jimenez-Urbieta H, et al
    Tau/alpha-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27001.
    PubMed     Text format     Abstract available


  279. KIM YJ, Jeon J, Shin J, Kim NY, et al
    Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27019.
    PubMed     Text format     Abstract available


  280. COLLIER TJ, Kanaan NM, Kordower JH
    Aging and Parkinson's disease: Different sides of the same coin?
    Mov Disord. 2017 May 18. doi: 10.1002/mds.27037.
    PubMed     Text format     Abstract available


  281. PILOTTO A, Heinzel S, Suenkel U, Lerche S, et al
    Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
    Mov Disord. 2017 May 16. doi: 10.1002/mds.27035.
    PubMed     Text format     Abstract available


  282. SHAHMOON S, Jahanshahi M
    Optimizing psychosocial adjustment after deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Mov Disord. 2017 May 15. doi: 10.1002/mds.27032.
    PubMed     Text format    


  283. YADAV AP, Nicolelis MAL
    Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.
    Mov Disord. 2017 May 12. doi: 10.1002/mds.27033.
    PubMed     Text format     Abstract available


  284. MEROLA A, Rosso M, Romagnolo A, Comi C, et al
    Peripheral neuropathy as marker of severe Parkinson's disease phenotype.
    Mov Disord. 2017 May 8. doi: 10.1002/mds.27025.
    PubMed     Text format    


  285. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.
    Mov Disord. 2017;32:724-725.
    PubMed     Text format    


  286. POSTUMA RB
    Sleep Disorders and RBD: What Would James Parkinson Think?
    Mov Disord. 2017;32:705-707.
    PubMed     Text format    


  287. ST LOUIS EK, Boeve AR, Boeve BF
    REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
    Mov Disord. 2017;32:645-658.
    PubMed     Text format     Abstract available


  288. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.
    Mov Disord. 2017;32:722-723.
    PubMed     Text format    


  289. MCKENNA D, Peever J
    Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder.
    Mov Disord. 2017;32:636-644.
    PubMed     Text format     Abstract available


  290. HOGL B, Stefani A
    Restless legs syndrome and periodic leg movements in patients with movement disorders: Specific considerations.
    Mov Disord. 2017;32:669-681.
    PubMed     Text format     Abstract available


    April 2017
  291. STROUWEN C, Molenaar EALM, Munks L, Keus SHJ, et al
    Training dual tasks together or apart in Parkinson's disease: Results from the DUALITY trial.
    Mov Disord. 2017 Apr 25. doi: 10.1002/mds.27014.
    PubMed     Text format     Abstract available


  292. DIEZ H, Cortes-Saladelafont E, Ormazabal A, Marmiese AF, et al
    Severe infantile parkinsonism because of a de novo mutation on DLP1 mitochondrial-peroxisomal protein.
    Mov Disord. 2017 Apr 24. doi: 10.1002/mds.27021.
    PubMed     Text format    


  293. OLSZEWSKA DA, Lynch T
    Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
    Mov Disord. 2017 Apr 22. doi: 10.1002/mds.27015.
    PubMed     Text format    


  294. BEAULIEU ML, Muller MLTM, Bohnen NI
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26994.
    PubMed     Text format    


  295. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.27009.
    PubMed     Text format    


  296. FERESHTEHNEJAD SM, Montplaisir JY, Pelletier A, Gagnon JF, et al
    Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26989.
    PubMed     Text format     Abstract available


  297. BURTE F, Houghton D, Lowes H, Pyle A, et al
    metabolic profiling of Parkinson's disease and mild cognitive impairment.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26992.
    PubMed     Text format     Abstract available


  298. KOOLE M, Laere KV, Ahmad R, Ceccarini J, et al
    Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.27005.
    PubMed     Text format    


  299. CACACE F, Mineo D, Viscomi MT, Latagliata EC, et al
    Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26982.
    PubMed     Text format     Abstract available


  300. YANG X, An R, Xi J, Zheng J, et al
    Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26996.
    PubMed     Text format    


  301. OLANOW CW, Kieburtz K, Leinonen M, Elmer L, et al
    A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26941.
    PubMed     Text format     Abstract available


  302. LIU G, Sterling NW, Kong L, Lewis MM, et al
    Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.27006.
    PubMed     Text format     Abstract available


  303. KORDOWER JH
    What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Mov Disord. 2017;32:483-484.
    PubMed     Text format    


  304. BALCK A, Klein C
    Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection.
    Mov Disord. 2017;32:527.
    PubMed     Text format    


    March 2017
  305. ORGAZ L, Gil GB
    Modulating mitochondrial pyruvate carrier: A promising therapeutic target in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26962.
    PubMed     Text format    


  306. FOX SH, Metman LV, Nutt JG, Brodsky M, et al
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976.
    PubMed     Text format     Abstract available


  307. PONT-SUNYER C, Tolosa E, Caspell-Garcia C, Coffey C, et al
    The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26964.
    PubMed     Text format     Abstract available


  308. LEHERICY S, Vaillancourt DE, Seppi K, Monchi O, et al
    The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26968.
    PubMed     Text format     Abstract available


  309. BARICHELLA M, Cereda E, Cassani E, Frazzitta G, et al
    A focus on Rome III criteria for the assessment of constipation in Parkinson's disease.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26974.
    PubMed     Text format    


  310. XU T, Wang S, Lalchandani RR, Ding JB, et al
    Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26938.
    PubMed     Text format     Abstract available


  311. MEROLA A, Romagnolo A, Comi C, Rosso M, et al
    Prevalence and burden of dysautonomia in advanced Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26970.
    PubMed     Text format    


  312. F HERNANDEZ L, Castela I, Ruiz-DeDiego I, Obeso JA, et al
    Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26947.
    PubMed     Text format     Abstract available


  313. ANDERKOVA L, Barton M, Rektorova I
    Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26956.
    PubMed     Text format     Abstract available


  314. PAGANO G, Niccolini F, Yousaf T, Wilson H, et al
    Urinary dysfunction in early de novo patients with Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26967.
    PubMed     Text format    


  315. PEREZ XA, Zhang D, Bordia T, Quik M, et al
    Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26955.
    PubMed     Text format     Abstract available


  316. HANSEN AK, Damholdt MF, Fedorova TD, Knudsen K, et al
    In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26961.
    PubMed     Text format     Abstract available


  317. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Text format     Abstract available


  318. MARRAS C
    What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.
    Mov Disord. 2017;32:364-365.
    PubMed     Text format    


    February 2017
  319. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Text format     Abstract available


  320. HORVATH K, Aschermann Z, Kovacs M, Makkos A, et al
    Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.
    Mov Disord. 2017 Feb 20. doi: 10.1002/mds.26960.
    PubMed     Text format     Abstract available


  321. MIKI Y, Yoshizawa T, Morohashi S, Seino Y, et al
    Neuropathology of PARK14 is identical to idiopathic Parkinson's disease.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26952.
    PubMed     Text format    


  322. ROSA M, Arlotti M, Marceglia S, Cogiamanian F, et al
    Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26953.
    PubMed     Text format    


  323. HILL-BURNS EM, Debelius JW, Morton JT, Wissemann WT, et al
    Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Mov Disord. 2017 Feb 14. doi: 10.1002/mds.26942.
    PubMed     Text format     Abstract available


  324. PONZO V, Di Lorenzo F, Brusa L, Schirinzi T, et al
    Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26931.
    PubMed     Text format     Abstract available


  325. ANSARI M, Sobhani S
    Impaired glutamate release in GPe astrocytes, disinhibits striatopallidal transmission in Parkinsonian mice.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26943.
    PubMed     Text format    


  326. GALLEA C, Ewenczyk C, Degos B, Welter ML, et al
    Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders.
    Mov Disord. 2017 Feb 6. doi: 10.1002/mds.26923.
    PubMed     Text format     Abstract available


  327. DEL REY NL, Blesa J
    Parkinson's disease: Oh my gut!
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26933.
    PubMed     Text format    


  328. MAHLKNECHT P, Krismer F, Poewe W, Seppi K, et al
    Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26932.
    PubMed     Text format     Abstract available


  329. MOLLER L, Kassubek J, Sudmeyer M, Hilker R, et al
    Manual MRI morphometry in Parkinsonian syndromes.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26921.
    PubMed     Text format     Abstract available


  330. STRAFELLA AP, Bohnen NI, Perlmutter JS, Eidelberg D, et al
    Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26907.
    PubMed     Text format     Abstract available


  331. OLANOW CW, Kordower JH
    Targeting alpha-Synuclein as a therapy for Parkinson's disease: The battle begins.
    Mov Disord. 2017;32:203-207.
    PubMed     Text format    


  332. ALBIN RL
    What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease.
    Mov Disord. 2017;32:179-180.
    PubMed     Text format    


  333. EBRAHIMI R, Sobhani S, Abbastabar M
    Whether the dissociation between toxicity and alpha-synuclein inclusion will be a possible therapy for Parkinson's disease or not?
    Mov Disord. 2017;32:210.
    PubMed     Text format    



  334. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed     Text format    


    January 2017
  335. MORBERG BM, Malling AS, Jensen BR, Gredal O, et al
    Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26927.
    PubMed     Text format    


  336. VIDENOVIC A
    Management of sleep disorders in Parkinson's disease and multiple system atrophy.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26918.
    PubMed     Text format     Abstract available


  337. NOYCE AJ, R'Bibo L, Peress L, Bestwick JP, et al
    PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26898.
    PubMed     Text format     Abstract available


  338. QUADRI M, Breedveld GJ, Chang HC, Yeh TH, et al
    Mutations in TMEM230 are not a common cause of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26900.
    PubMed     Text format    


  339. MOHASEL S, Sobhani S
    The role of amyloidogenic proteins as a meeting point of type 2 diabetes and Parkinson's disease pathways.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26897.
    PubMed     Text format    


  340. VISANJI NP, Bhudhikanok GS, Mestre TA, Ghate T, et al
    Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26896.
    PubMed     Text format     Abstract available


  341. SCHNEIDER SA, Bras J
    Mouse models of kufor-rakeb disease link Parkinson's disease closer to neuronal ceroid lipofuscinosis, suggesting lysosomal dysfunction as shared mechanism.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26899.
    PubMed     Text format    


  342. BESTE C, Muckschel M, Rosales R, Domingo A, et al
    Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.
    Mov Disord. 2017 Jan 6. doi: 10.1002/mds.26895.
    PubMed     Text format     Abstract available


  343. SPATARO N, Roca-Umbert A, Cervera-Carles L, Valles M, et al
    Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.
    Mov Disord. 2017;32:165-169.
    PubMed     Text format     Abstract available


  344. ZHANG M, Xi Z, Misquitta K, Sato C, et al
    C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism.
    Mov Disord. 2017;32:158-162.
    PubMed     Text format     Abstract available


  345. HARIZ M, Obeso JA
    What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease.
    Mov Disord. 2017;32:2-4.
    PubMed     Text format    


  346. BLUMENFELD Z, Koop MM, Prieto TE, Shreve LA, et al
    Sixty-hertz stimulation improves bradykinesia and amplifies subthalamic low-frequency oscillations.
    Mov Disord. 2017;32:80-88.
    PubMed     Text format     Abstract available


  347. CHO H, Choi JY, Hwang MS, Lee SH, et al
    Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy.
    Mov Disord. 2017;32:134-140.
    PubMed     Text format     Abstract available


  348. VALSKY D, Marmor-Levin O, Deffains M, Eitan R, et al
    Stop! border ahead: Automatic detection of subthalamic exit during deep brain stimulation surgery.
    Mov Disord. 2017;32:70-79.
    PubMed     Text format     Abstract available


    December 2016
  349. LANGLEY J, Huddleston DE, Sedlacik J, Boelmans K, et al
    Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26883.
    PubMed     Text format     Abstract available


  350. RAHMANI F, Kamalian A, Aarabi MH
    New evidence comes to light: How is alpha-synuclein aggregation related to mitochondrial protein import in Parkinson's disease?
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26889.
    PubMed     Text format    


  351. BLAUWENDRAAT C, Nalls MA, Federoff M, Pletnikova O, et al
    ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26886.
    PubMed     Text format    


  352. SENEK M, Nielsen EI, Nyholm D
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26855.
    PubMed     Text format     Abstract available


  353. PAL GD, Ouyang B, Serrano G, Shill HA, et al
    Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26882.
    PubMed     Text format     Abstract available


  354. DZAMKO N, Gysbers AM, Bandopadhyay R, Bolliger MF, et al
    LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26892.
    PubMed     Text format     Abstract available


  355. MARTINEZ-MARTIN P
    What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26885.
    PubMed     Text format     Abstract available


  356. GOETZ CG, Liu Y, Stebbins GT, Wang L, et al
    Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Mov Disord. 2016;31:1865-1873.
    PubMed     Text format     Abstract available


  357. WILLIS AW, Thibault DP, Schmidt PN, Dorsey ER, et al
    Hospital care for mental health and substance abuse conditions in Parkinson's disease.
    Mov Disord. 2016;31:1810-1819.
    PubMed     Text format     Abstract available


  358. SHI CH, Zhang SY, Yang ZH, Yang J, et al
    A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.
    Mov Disord. 2016;31:1905-1909.
    PubMed     Text format     Abstract available


    November 2016
  359. DE PABLO-FERNANDEZ E, Courtney R, Holton JL, Warner TT, et al
    Hypothalamic alpha-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease.
    Mov Disord. 2016 Nov 28. doi: 10.1002/mds.26868.
    PubMed     Text format    


  360. KNUDSEN K, Krogh K, Ostergaard K, Borghammer P, et al
    Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26866.
    PubMed     Text format     Abstract available


  361. PILLAS M, Selai C, Schrag A
    Rasch analysis of the carers quality of life questionnaire for parkinsonism.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26877.
    PubMed     Text format     Abstract available


  362. RAUSCHENDORF MA, Jost M, Stock F, Zimmer A, et al
    Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26876.
    PubMed     Text format    


  363. HE YC, Huang P, Li QQ, Sun Q, et al
    TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26875.
    PubMed     Text format    


  364. POLITIS M, Sauerbier A, Loane C, Pavese N, et al
    Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Mov Disord. 2016 Nov 17. doi: 10.1002/mds.26848.
    PubMed     Text format     Abstract available


  365. GALIMBERTI D, Cioffi SM, Fenoglio C, Serpente M, et al
    Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872.
    PubMed     Text format    


  366. FIFEL K
    Alterations of the circadian system in Parkinson's disease patients.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26865.
    PubMed     Text format     Abstract available


  367. ISOTALO J, Vahlberg T, Kaasinen V
    Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26862.
    PubMed     Text format    


  368. XIE T, Kang UJ
    Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26861.
    PubMed     Text format    


  369. GAARE JJ, Skeie GO, Tzoulis C, Larsen JP, et al
    Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.
    PubMed     Text format     Abstract available


  370. PINTO DE SOUZA C, Hamani C, Oliveira Souza C, Lopez Contreras WO, et al
    Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26850.
    PubMed     Text format     Abstract available


  371. KLETTNER A, Tholey A, Wiegandt A, Richert E, et al
    Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26863.
    PubMed     Text format     Abstract available


  372. BEUDEL M, Oswal A, Jha A, Foltynie T, et al
    Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26860.
    PubMed     Text format    


  373. DI BIASE L, Fasano A
    Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?"
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26859.
    PubMed     Text format    


  374. NEUMANN WJ, Kuhn AA
    Subthalamic beta power-Unified Parkinson's disease rating scale III correlations require akinetic symptoms.
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26858.
    PubMed     Text format    


  375. SGAMBATO-FAURE V
    Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms.
    Mov Disord. 2016 Nov 2. doi: 10.1002/mds.26840.
    PubMed     Text format    


    October 2016
  376. FOO JN, Lee J, Tan LC, Liu J, et al
    Large 3-Mb deletions at 22q11.2 locus in parkinson's disease and schizophrenia.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26822.
    PubMed     Text format    


  377. HUGHES KC, Gao X, Kim IY, Rimm EB, et al
    Intake of antioxidant vitamins and risk of parkinson's disease.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26819.
    PubMed     Text format     Abstract available


  378. TINAZZI M, Geroin C, Gandolfi M, Smania N, et al
    Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26829.
    PubMed     Text format     Abstract available


  379. MANGESIUS S, Krismer F, Gizewski ER, Muller C, et al
    1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26823.
    PubMed     Text format    


  380. SAVICA R, Grossardt BR, Bower JH, Ahlskog JE, et al
    Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26839.
    PubMed     Text format     Abstract available


  381. TARSY D
    Addition of a virtual reality component to treadmill training to reduce fall risk in older adults, including individuals with Parkinson's disease.
    Mov Disord. 2016 Oct 19. doi: 10.1002/mds.26843.
    PubMed     Text format    


  382. KHODADADI H, Azcona LJ, Aghamollaii V, Omrani MD, et al
    PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26824.
    PubMed     Text format     Abstract available


  383. TROSTER AI, Jankovic J, Tagliati M, Peichel D, et al
    Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26827.
    PubMed     Text format     Abstract available


  384. PYLE A, Lowes H, Brennan R, Kurzawa-Akanbi M, et al
    Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26825.
    PubMed     Text format    


  385. BALINT B, Bhatia KP
    SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia.
    Mov Disord. 2016 Oct 14. doi: 10.1002/mds.26821.
    PubMed     Text format    


  386. KLEIN C, Lochte T, Delamonte SM, Braenne I, et al
    PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical Features and Neuropathology.
    Mov Disord. 2016 Oct 6. doi: 10.1002/mds.26814.
    PubMed     Text format    


  387. POLLI A, Weis L, Biundo R, Thacker M, et al
    Anatomical and functional correlates of persistent pain in parkinson's disease.
    Mov Disord. 2016 Oct 5. doi: 10.1002/mds.26826.
    PubMed     Text format     Abstract available


    September 2016
  388. PONS R, Kekou K, Antonellou R, Svingou M, et al
    Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease.
    Mov Disord. 2016 Sep 26. doi: 10.1002/mds.26807.
    PubMed     Text format    


  389. SVENSSON E, Horvath-Puho E, Stokholm MG, Sorensen HT, et al
    Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26761.
    PubMed     Text format     Abstract available


  390. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naive cohort.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26742.
    PubMed     Text format     Abstract available


  391. WONG YC, Krainc D
    Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26802.
    PubMed     Text format     Abstract available


  392. KETT LR, Dauer WT
    Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26797.
    PubMed     Text format     Abstract available


  393. RIEDEL O
    Bringing light into the darkness: Dependence in Parkinson's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26795.
    PubMed     Text format    


  394. DELVAL A, Rambour M, Tard C, Dujardin K, et al
    Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26762.
    PubMed     Text format     Abstract available


    April 2016
  395. WEISS D, Herrmann S, Wang L, Schulte C, et al
    Alpha-synuclein gene variants may predict neurostimulation outcome.
    Mov Disord. 2016;31:601-3.
    PubMed     Text format    


  396. LAWTON M, Kasten M, May MT, Mollenhauer B, et al
    Validation of conversion between mini-mental state examination and montreal cognitive assessment.
    Mov Disord. 2016;31:593-6.
    PubMed     Text format     Abstract available


  397. LANG AE, Rodriguez RL, Boyd JT, Chouinard S, et al
    Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Mov Disord. 2016;31:538-46.
    PubMed     Text format     Abstract available


    March 2016
  398. MESTRE TA, Lang AE, Okun MS
    Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mov Disord. 2016;31:290-6.
    PubMed     Text format     Abstract available


  399. OROPESA-RUIZ JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, et al
    Low serum uric acid levels in progressive supranuclear palsy.
    Mov Disord. 2016;31:402-5.
    PubMed     Text format     Abstract available


  400. WILE DJ, Dinelle K, Vafai N, McKenzie J, et al
    A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
    Mov Disord. 2016;31:405-9.
    PubMed     Text format     Abstract available


  401. WALTER U, Muller JU, Rosche J, Kirsch M, et al
    Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location.
    Mov Disord. 2016;31:302-9.
    PubMed     Text format     Abstract available


    February 2016
  402. STEFANOVA N, Kordower JH, Wenning GK
    Preface.
    Mov Disord. 2016;31:151.
    PubMed     Text format    


  403. RICCIARDI L, Petrucci S, Di Giuda D, Serra L, et al
    The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation.
    Mov Disord. 2016;31:257-8.
    PubMed     Text format    


  404. RUFFMANN C, Parkkinen L
    Gut Feelings About alpha-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?
    Mov Disord. 2016;31:193-202.
    PubMed     Text format     Abstract available


  405. CALO L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M, et al
    Synaptic failure and alpha-synuclein.
    Mov Disord. 2016;31:169-77.
    PubMed     Text format     Abstract available


  406. BERGSTROM AL, Kallunki P, Fog K
    Development of Passive Immunotherapies for Synucleinopathies.
    Mov Disord. 2016;31:203-13.
    PubMed     Text format     Abstract available


  407. VALERA E, Masliah E
    Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Mov Disord. 2016;31:225-34.
    PubMed     Text format     Abstract available


  408. MCCANN H, Cartwright H, Halliday GM
    Neuropathology of alpha-synuclein propagation and braak hypothesis.
    Mov Disord. 2016;31:152-60.
    PubMed     Text format     Abstract available


  409. SCHNEEBERGER A, Tierney L, Mandler M
    Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Mov Disord. 2016;31:214-24.
    PubMed     Text format     Abstract available


    January 2016
  410. CARTA M, Cenci MA
    On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Mov Disord. 2016;31:149.
    PubMed     Text format    


  411. OLANOW CW, Poewe W
    Eldad Melamed 1942-2015: Ave atque--A memorial.
    Mov Disord. 2016;31:39-40.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: